Lesson · 2 min read · Amycretin
Amycretin: what the studies show
Amycretin is now called zenagamtide
Novo Nordisk now uses zenagamtide for the molecule previously called amycretin. Its development code is NNC0487-0111. It is one investigational molecule with GLP-1 and amylin receptor activity. It is separate from the two-molecule cagrilintide and semaglutide combination.
No FDA-approved amycretin or zenagamtide product was identified at this review. Novo's November 2026 report describes phase 3 development for both routes, including the oral AMAZE 9 trial started in September. Starting a trial does not establish efficacy.
Oral and injected trial results
A 36-week phase 2 study in adults with type 2 diabetes included 262 participants in the weekly subcutaneous cohort and 186 in the daily oral cohort. Participants used metformin, with or without an SGLT2 inhibitor. Each route improved HbA1c compared with its placebo group.
The two publications share NCT06542874. They count as one study, and separate placebo comparisons do not establish that tablets and injections work equally well. Gastrointestinal adverse events occurred.
Route-specific limits
Oral results do not establish an injection schedule. Identify whether each result concerns tablets or subcutaneous treatment. Long-term cardiovascular effects and comparative tolerability between routes remain unresolved by this phase 2 study.
Quick check
How should the oral and subcutaneous phase 2 publications under NCT06542874 be counted?
Sources
- Novo Nordisk, June 6, 2026: Investigational zenagamtide also known as amycretin
- CDSCO, March 5, 2026: NNC0487-0111 and zenagamtide phase 3 protocol identity
- Novo Nordisk, November 4, 2026: Third-quarter report with oral and subcutaneous zenagamtide phase 3 updates
- Mora et al., July 30, 2026: Subcutaneous zenagamtide phase 2 results, NCT06542874
- Mora et al., July 30, 2026: Oral zenagamtide phase 2 results, NCT06542874
- Lancet, October 24, 2026: Correction to oral zenagamtide phase 2 report
Peptiday editorial summary, not clinically reviewed, November 6, 2026. For education only, not medical advice. Talk to a clinician before starting, stopping or changing treatment.